Natural history of malignant bone disease in gastric cancer: final results of a multicenter bone metastasis survey.
<h4>Background</h4>Bone metastasis represents an increasing clinical problem in advanced gastric cancer (GC) as disease-related survival improves. In literature, few data on the natural history of bone disease in GC are available.<h4>Patients and methods</h4>Data on clinicopa...
Guardado en:
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2013
|
Materias: | |
Acceso en línea: | https://doaj.org/article/ba465d2c21ca4ee5b7057c23eeaeff1e |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
id |
oai:doaj.org-article:ba465d2c21ca4ee5b7057c23eeaeff1e |
---|---|
record_format |
dspace |
spelling |
oai:doaj.org-article:ba465d2c21ca4ee5b7057c23eeaeff1e2021-11-18T08:49:19ZNatural history of malignant bone disease in gastric cancer: final results of a multicenter bone metastasis survey.1932-620310.1371/journal.pone.0074402https://doaj.org/article/ba465d2c21ca4ee5b7057c23eeaeff1e2013-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24204569/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Background</h4>Bone metastasis represents an increasing clinical problem in advanced gastric cancer (GC) as disease-related survival improves. In literature, few data on the natural history of bone disease in GC are available.<h4>Patients and methods</h4>Data on clinicopathology, skeletal outcomes, skeletal-related events (SREs), and bone-directed therapies for 208 deceased GC patients with evidence of bone metastasis were statistically analyzed.<h4>Results</h4>Median time to bone metastasis was 8 months (CI 95%, 6.125-9.875 months) considering all included patients. Median number of SREs/patient was one. Less than half of the patients (31%) experienced at least one and only 4 and 2% experienced at least two and three events, respectively. Median times to first and second SRE were 2 and 4 months, respectively. Median survival was 6 months after bone metastasis diagnosis and 3 months after first SRE. Median survival in patients who did not experience SREs was 5 months. Among patients who received zoledronic acid before the first SRE, the median time to appearance of first SRE was significantly prolonged compared to control (7 months vs 4 months for control; P: 0.0005).<h4>Conclusions</h4>To our knowledge, this retrospective analysis is the largest multicenter study to demonstrate that bone metastases from GC are not so rare, are commonly aggressive and result in relatively early onset of SREs in the majority of patients. Indeed, our large study, which included 90 patients treated with ZOL, showed, for the first time in literature, a significant extension of time to first SRE and increase in the median survival time after diagnosis of bone metastasis. Taken together, these data may support the beneficial effects of ZOL in GC patients.Nicola SilvestrisFrancesco PantanoToni IbrahimTeresa GamucciFernando De VitaTeresa Di PalmaPaolo PedrazzoliSandro BarniAntonio BernardoAntonio FebbraroMaria Antonietta SatolliPaola BertocchiVincenzo CatalanoElisa GiommoniAlessandro ComandoneEvaristo MaielloFerdinando RiccardiRaimondo FerraraAntonio TroguRossana BerardiSilvana LeoAlessandro BertoliniFrancesco AngeliniSaverio CinieriAntonio RussoSalvatore PiscontiAnna Elisabetta BrunettiAmalia AzzaritiDaniele SantiniPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 8, Iss 10, p e74402 (2013) |
institution |
DOAJ |
collection |
DOAJ |
language |
EN |
topic |
Medicine R Science Q |
spellingShingle |
Medicine R Science Q Nicola Silvestris Francesco Pantano Toni Ibrahim Teresa Gamucci Fernando De Vita Teresa Di Palma Paolo Pedrazzoli Sandro Barni Antonio Bernardo Antonio Febbraro Maria Antonietta Satolli Paola Bertocchi Vincenzo Catalano Elisa Giommoni Alessandro Comandone Evaristo Maiello Ferdinando Riccardi Raimondo Ferrara Antonio Trogu Rossana Berardi Silvana Leo Alessandro Bertolini Francesco Angelini Saverio Cinieri Antonio Russo Salvatore Pisconti Anna Elisabetta Brunetti Amalia Azzariti Daniele Santini Natural history of malignant bone disease in gastric cancer: final results of a multicenter bone metastasis survey. |
description |
<h4>Background</h4>Bone metastasis represents an increasing clinical problem in advanced gastric cancer (GC) as disease-related survival improves. In literature, few data on the natural history of bone disease in GC are available.<h4>Patients and methods</h4>Data on clinicopathology, skeletal outcomes, skeletal-related events (SREs), and bone-directed therapies for 208 deceased GC patients with evidence of bone metastasis were statistically analyzed.<h4>Results</h4>Median time to bone metastasis was 8 months (CI 95%, 6.125-9.875 months) considering all included patients. Median number of SREs/patient was one. Less than half of the patients (31%) experienced at least one and only 4 and 2% experienced at least two and three events, respectively. Median times to first and second SRE were 2 and 4 months, respectively. Median survival was 6 months after bone metastasis diagnosis and 3 months after first SRE. Median survival in patients who did not experience SREs was 5 months. Among patients who received zoledronic acid before the first SRE, the median time to appearance of first SRE was significantly prolonged compared to control (7 months vs 4 months for control; P: 0.0005).<h4>Conclusions</h4>To our knowledge, this retrospective analysis is the largest multicenter study to demonstrate that bone metastases from GC are not so rare, are commonly aggressive and result in relatively early onset of SREs in the majority of patients. Indeed, our large study, which included 90 patients treated with ZOL, showed, for the first time in literature, a significant extension of time to first SRE and increase in the median survival time after diagnosis of bone metastasis. Taken together, these data may support the beneficial effects of ZOL in GC patients. |
format |
article |
author |
Nicola Silvestris Francesco Pantano Toni Ibrahim Teresa Gamucci Fernando De Vita Teresa Di Palma Paolo Pedrazzoli Sandro Barni Antonio Bernardo Antonio Febbraro Maria Antonietta Satolli Paola Bertocchi Vincenzo Catalano Elisa Giommoni Alessandro Comandone Evaristo Maiello Ferdinando Riccardi Raimondo Ferrara Antonio Trogu Rossana Berardi Silvana Leo Alessandro Bertolini Francesco Angelini Saverio Cinieri Antonio Russo Salvatore Pisconti Anna Elisabetta Brunetti Amalia Azzariti Daniele Santini |
author_facet |
Nicola Silvestris Francesco Pantano Toni Ibrahim Teresa Gamucci Fernando De Vita Teresa Di Palma Paolo Pedrazzoli Sandro Barni Antonio Bernardo Antonio Febbraro Maria Antonietta Satolli Paola Bertocchi Vincenzo Catalano Elisa Giommoni Alessandro Comandone Evaristo Maiello Ferdinando Riccardi Raimondo Ferrara Antonio Trogu Rossana Berardi Silvana Leo Alessandro Bertolini Francesco Angelini Saverio Cinieri Antonio Russo Salvatore Pisconti Anna Elisabetta Brunetti Amalia Azzariti Daniele Santini |
author_sort |
Nicola Silvestris |
title |
Natural history of malignant bone disease in gastric cancer: final results of a multicenter bone metastasis survey. |
title_short |
Natural history of malignant bone disease in gastric cancer: final results of a multicenter bone metastasis survey. |
title_full |
Natural history of malignant bone disease in gastric cancer: final results of a multicenter bone metastasis survey. |
title_fullStr |
Natural history of malignant bone disease in gastric cancer: final results of a multicenter bone metastasis survey. |
title_full_unstemmed |
Natural history of malignant bone disease in gastric cancer: final results of a multicenter bone metastasis survey. |
title_sort |
natural history of malignant bone disease in gastric cancer: final results of a multicenter bone metastasis survey. |
publisher |
Public Library of Science (PLoS) |
publishDate |
2013 |
url |
https://doaj.org/article/ba465d2c21ca4ee5b7057c23eeaeff1e |
work_keys_str_mv |
AT nicolasilvestris naturalhistoryofmalignantbonediseaseingastriccancerfinalresultsofamulticenterbonemetastasissurvey AT francescopantano naturalhistoryofmalignantbonediseaseingastriccancerfinalresultsofamulticenterbonemetastasissurvey AT toniibrahim naturalhistoryofmalignantbonediseaseingastriccancerfinalresultsofamulticenterbonemetastasissurvey AT teresagamucci naturalhistoryofmalignantbonediseaseingastriccancerfinalresultsofamulticenterbonemetastasissurvey AT fernandodevita naturalhistoryofmalignantbonediseaseingastriccancerfinalresultsofamulticenterbonemetastasissurvey AT teresadipalma naturalhistoryofmalignantbonediseaseingastriccancerfinalresultsofamulticenterbonemetastasissurvey AT paolopedrazzoli naturalhistoryofmalignantbonediseaseingastriccancerfinalresultsofamulticenterbonemetastasissurvey AT sandrobarni naturalhistoryofmalignantbonediseaseingastriccancerfinalresultsofamulticenterbonemetastasissurvey AT antoniobernardo naturalhistoryofmalignantbonediseaseingastriccancerfinalresultsofamulticenterbonemetastasissurvey AT antoniofebbraro naturalhistoryofmalignantbonediseaseingastriccancerfinalresultsofamulticenterbonemetastasissurvey AT mariaantoniettasatolli naturalhistoryofmalignantbonediseaseingastriccancerfinalresultsofamulticenterbonemetastasissurvey AT paolabertocchi naturalhistoryofmalignantbonediseaseingastriccancerfinalresultsofamulticenterbonemetastasissurvey AT vincenzocatalano naturalhistoryofmalignantbonediseaseingastriccancerfinalresultsofamulticenterbonemetastasissurvey AT elisagiommoni naturalhistoryofmalignantbonediseaseingastriccancerfinalresultsofamulticenterbonemetastasissurvey AT alessandrocomandone naturalhistoryofmalignantbonediseaseingastriccancerfinalresultsofamulticenterbonemetastasissurvey AT evaristomaiello naturalhistoryofmalignantbonediseaseingastriccancerfinalresultsofamulticenterbonemetastasissurvey AT ferdinandoriccardi naturalhistoryofmalignantbonediseaseingastriccancerfinalresultsofamulticenterbonemetastasissurvey AT raimondoferrara naturalhistoryofmalignantbonediseaseingastriccancerfinalresultsofamulticenterbonemetastasissurvey AT antoniotrogu naturalhistoryofmalignantbonediseaseingastriccancerfinalresultsofamulticenterbonemetastasissurvey AT rossanaberardi naturalhistoryofmalignantbonediseaseingastriccancerfinalresultsofamulticenterbonemetastasissurvey AT silvanaleo naturalhistoryofmalignantbonediseaseingastriccancerfinalresultsofamulticenterbonemetastasissurvey AT alessandrobertolini naturalhistoryofmalignantbonediseaseingastriccancerfinalresultsofamulticenterbonemetastasissurvey AT francescoangelini naturalhistoryofmalignantbonediseaseingastriccancerfinalresultsofamulticenterbonemetastasissurvey AT saveriocinieri naturalhistoryofmalignantbonediseaseingastriccancerfinalresultsofamulticenterbonemetastasissurvey AT antoniorusso naturalhistoryofmalignantbonediseaseingastriccancerfinalresultsofamulticenterbonemetastasissurvey AT salvatorepisconti naturalhistoryofmalignantbonediseaseingastriccancerfinalresultsofamulticenterbonemetastasissurvey AT annaelisabettabrunetti naturalhistoryofmalignantbonediseaseingastriccancerfinalresultsofamulticenterbonemetastasissurvey AT amaliaazzariti naturalhistoryofmalignantbonediseaseingastriccancerfinalresultsofamulticenterbonemetastasissurvey AT danielesantini naturalhistoryofmalignantbonediseaseingastriccancerfinalresultsofamulticenterbonemetastasissurvey |
_version_ |
1718421284590714880 |